-
Product Insights
NewNet Present Value Model: Protara Therapeutics Inc’s Intrachol
Empower your strategies with our Net Present Value Model: Protara Therapeutics Inc's Intrachol report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MRNA-4157 in Squamous Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MRNA-4157 in Squamous Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MRNA-4157 in Squamous Non-Small Cell Lung Cancer Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Amdizalisib in Splenic Marginal Zone B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Amdizalisib in Splenic Marginal Zone B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Amdizalisib in Splenic Marginal Zone B-Cell Lymphoma Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MRNA-4157 in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MRNA-4157 in Metastatic Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MRNA-4157 in Metastatic Melanoma Drug Details: mRNA-4157 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MK-3475A in Metastatic Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MK-3475A in Metastatic Renal Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MK-3475A in Metastatic Renal Cell Carcinoma Drug Details: MK-3475A...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – INBRX-106 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - INBRX-106 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. INBRX-106 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lurbinectedin in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lurbinectedin in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lurbinectedin in Triple-Negative Breast Cancer (TNBC) Drug Details: Lurbinectedin (Zepzelca)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AT-101 in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AT-101 in Marginal Zone B-cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AT-101 in Marginal Zone B-cell Lymphoma Drug Details: AT-101...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Y-101D in Metastatic Hepatocellular Carcinoma (HCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Y-101D in Metastatic Hepatocellular Carcinoma (HCC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Y-101D in Metastatic Hepatocellular Carcinoma (HCC) Drug Details: Bi-specific...
-
Product Insights
Seasonal Influenza Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Seasonal Influenza Clinical Trial Report Overview A total of 310 seasonal influenza clinical trials were conducted as of February 2024. The Seasonal Influenza clinical trial report provides a comprehensive understanding of the seasonal influenza clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions ·       North America ·       ...